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INTRODUCTION
Mycoplasma pneumoniae and Chlamydia pneumoniae are com-
mon etiologies of atypical respiratory infection. Several recent
studies have shown that these organisms play an important
role in the acute exacerbation of bronchial asthma and chronic
obstructive pulmonary disease (COPD) (1-4). The role of res-
piratory infection has been recently suggested for the patho-
genesis of bronchial asthma, and atypical organisms such as
M. pneumoniae and C. pneumoniae have been recently linked to
the onset of asthma (5-7). A few clinical and experimental
animal studies have suggested that peripheral airways diseases
may be due to the cumulative effects of recurrent respiratory
infections over an extended period of time (8). Therefore, the
significance of atypical respiratory infections for the develop-
ment of COPD is now getting a lot of the limelight.
The purpose of this study is to evaluate the seroprevalences
of M. pneumoniae and C. pneumoniae in clinically stable asthma
and COPD, and to compare with control subjects.
MATERIALS AND METHODS
Study subjects
One hundred forty patients who had been serologically test-
ed for M. pneumoniae and C. pneumoniae from November 2002
to August 2003 were enrolled as subjects in our study. The
clinical charts were reviewed retrospectively, and the subjects
were divided into the asthma group, the COPD group, and
the control group according to history, physical examination,
and the results of spirometry and methacholine challenge test.
The diagnosis of asthma was based on demonstration of rever-
sible airway obstruction (post-bronchodilator FEV1 increase
of ≥15%) and was confirmed by airway hyperreactivity to
methacholine (i.e., provocative concentration of methacholine
producing a 20% reduction in FEV1 [PC20] of <8 mg/mL).
Entry criteria for the COPD group were the following three
conditions: 1) age above 40 yr, 2) smoking history of more
than 20 pack-years, 3) maximal FEV1/FVC ratio of less than
0.7 and FEV1 of less than 80% of the predicted value. The
patients that were excluded from the asthma group and the
COPD group were included to the control group. All enrolled
patients did not show any clinical signs of acute exacerbation
at that time such as worsening of dyspnea, increased sputum
volume, new expectoration of purulent sputum or increased
sputum purulence. All the subjects gave their informed con-
sent and the experimental protocol was accepted by the Insti-
tutional Review Board of Chonbuk National University Hos-
pital, Jeonju, Korea.
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Seroprevalence of Mycoplasma pneumoniae and Chlamydia 
pneumoniae in Stable Asthma and Chronic Obstructive Pulmonary
Disease
Mycoplasma pneumoniae and Chlamydia pneumoniae have been suggested to take
part in the acute exacerbation of bronchial asthma and chronic obstructive pulmonary
disease (COPD). Several studies have questioned whether they may play pathogenic
roles in connection with bronchial asthma and COPD. This study was designed to
evaluate the seroprevalences of M. pneumoniae and C. pneumoniae in stable asthma
and COPD patients, and to compare with control patients. The medical records of
one hundred forty patients who underwent M. pneumoniae and C. pneumoniae
serology were retrospectively reviewed. Seroprevalences of M. pneumoniae and
C. pneumoniae in the asthma group (11.1% and 8.3%, respectively) were higher
than in the control group (4.4% and 2.2%, respectively) without statistical significance.
The seroprevalence of M. pneumoniae in the COPD group (16.9%) was significantly
higher than in the control group, and the seroprevalence of C. pneumoniae in the
COPD group (3.4%) was higher than in the control group without statistical signifi-
cance. This study raises important questions about the relation of M. pneumoniae
and C. pneumoniae infection with stable asthma or COPD.
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Serologic test 
Anti-Mycoplasma antibody titer was detected by the indirect
agglutination method (Serodia Myco II, Fujirebio, Japan) that
anti-Mycoplasma reacted with artificial serum contained mem-
brane of M. pneumoniae. According to the manufacturer’s inst-
ructions, the serologic evidence of infection with M. pneumo-
niae was defined as an antibody titer of higher than 1:64, or
a four-fold rise in the convalescent serum compared with base
as detected on two tests.
Antibody to C. pneumoniae was detected by the microim-
munofluorescence (MIF) test using IgG Micro-IF Kit (Fuller
Laboratories, California, U.S.A.) and IgM Micro-IF Kit (Vir-
cell, Santa Fe-Granada, Spain). Serologic evidence of an infec-
tion with C. pneumoniae was defined as an IgG titer of higher
than 1:512 or an IgM titer of higher than 1:20.
Statistical analysis 
Data are expressed as mean±standard deviation. Statistical
comparisons were performed using the Mann-Whitney U test
and chi-square test. For all analyses, all tests were 2-sided, with
the level of significance defined as a p-value of 0.05 or less.
RESULTS
Subject populations and characteristics
A total of 140 patients were enrolled. The average age of
the subjects was 62.7±11.0 yr, and there were 85 males and
55 females. There were 36 patients in the asthma group, 59
patients in the COPD group, and 45 patients in the control
group. Because the three groups had different characteristics
on the demographic parameters and pulmonary function test,
statistical comparisons were performed between control and
asthmatic groups, and control and COPD groups (Table 1, 2).
Comparison between asthmatic group and control group
The seroprevalence of M. pneumoniae in the stable asthmatic
group (11.1%) showed as being higher than the control group
(4.4%), and this was without statically significance (p=0.255)
(Table 3). The seroprevalence of C. pneumoniae in the stable
asthmatic group (8.3%) showed as being higher than the con-
trol group (2.2%), and this was not statically significant (p=
0.207).
Comparison between COPD group and control group
The seroprevalence of M. pneumoniae in the COPD group
(16.9%) was significantly higher than the control group (p=
0.048), and the seroprevalence of C. pneumoniae in the COPD
group (3.4%) was higher than the control group without sta-
tistical significance (p=0.724) (Table 4).
DISCUSSION
M. pneumoniae and C. pneumoniae are common etiologic bac-
Parameters Asthma group Control group
Subjects (n) 36 45
Gender (M/F) 20/16 23/22
Age (yr) 60.0±17.6 57.4±19.0
FEV1 (L) 2.0±0.6 2.3±0.8
FEV1 (% pred) 73.0±20.0 93.1±17.5
BDR (% changed) 21.0±7.0 <15%
PC20 (mg/mL) 7.05±5.0 >16
Table 1. Comparison of demographic characteristics and spiro-
metry of the asthma group and the control group
Data are presented as mean±SD. n, number; M, male; F, female; FEV1,
forced expiratory volume in one second; % pred, percent of predicted
value; BDR, bronchodilator response; PC20, provocative concentration
of methacholine causing FEV1 to fall by 20%.
Asthma group
(n=36)
Control group
(n=45)
p value
M. pneumoniae  4 (11.1%) 2 (4.4%) 0.255
C. pneumoniae  3 (8.3%) 1 (2.2%) 0.207
Table 3. Mycoplasma pneumoniae and Chlamydia pneumoniae
seroprevalences in the asthma and control groups
Data are presented as the number of seropositive patients (seropreva-
lence %). n, number of total patients.
COPD group
(n=59)
Control group
(n=45)
p value
M. pneumoniae 10 (16.9%) 2 (4.4%) 0.048
C. pneumoniae  3 (3.4%) 1 (2.2%) 0.724
Table 4. Mycoplasma pneumoniae and Chlamydia pneumoniae
seroprevalences in the COPD and control groups
Data are presented as the number of seropositive patients (seropreva-
lence %) n, number of total patients.
Control group COPD group
Subjects (n) 59 45
Gender (M/F) 42/17 23/22
Age (yr) 68.5±10.1 57.4±19.0
FEV1 (L) 1.4±0.6 2.3±0.8
FEV1 (% pred) 63.9±22.0 93.1±17.5
FEV1/FVC (%) 58.0±10.7 >70%
Smoking (p/yr) 51.3±31.5 42.9±30.3
Table 2. Comparison of demographic characteristics, smoking,
and spirometry of the COPD group and the control group
Data are presented as mean±SD. n, number; M, male; F, female; FEV1,
forced expiratory volume in one second; % pred, percent of predicted
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teria causing respiratory infection and responsible for commu-
nity acquired pneumonia. Moreover, respiratory infections
have been shown to play an important role in the acute exac-
erbation of bronchial asthma and COPD. Liberman et al. (3)
have reported that the seroprevalence of M. pneumoniae in bron-
chial asthma patients with acute exacerbation was 18%, and
the seroprevalence of C. pneumoniae in these patients was 8%.
They have also reported that the seroprevalence of M. pneumo-
niae in COPD patients with acute exacerbation was 14.2%
(4). From the results of several studies, the putative role of
atypical respiratory pathogens, such as M. pneumoniae and C.
pneumoniae, in the development of asthma or COPD has been
suggested.
Since bacterial infections are known to impair mucociliary
clearance and to increase mucus production in the lung, it has
been proposed that certain bacterial infections may cause chro-
nic lower airway inflammation. Organisms primarily impli-
cated in this process include M. pneumoniae and C. pneumoniae
(9-11). Hahn (12) has reviewed all the relevant medline arti-
cles from January 1984 to March 1999, and he has reported
that of 18 controlled epidemiologic studies (with over 4,000
cases/controls), 15 studies have found significant associations
between C. pneumoniae infection and asthma, and 5 of 6 stud-
ies (with over 1,000 cases/controls) have reported significant
associations between C. pneumoniae infection and COPD. 
The most important cause of COPD is well known to be
smoking. However, the pathogenesis of asthma is not defini-
tive and it may be mutifactorial, and so this ambiguity has
gathered interest for the association of atypical respiratory
pathogens with the pathogenesis of asthma than COPD (13-
18). Martin et al. (11) studied M. pneumoniae and C. pneumo-
niae infection rates in chronic bronchial asthma patients and
normal control subjects by using polymerase chain reaction
(PCR), culture, and serologic test. Their results showed that
M. pneumoniae and C. pneumoniae positive rates in the bronchial
asthma group were significantly higher than control group.
In contrast to the results of many studies, Foschino Barbaro
et al. reported that the seroprevalence of C. pneumoniae in stable
asthmatics was comparable with the controls (19). Although
statistical significance was not noted, our data showed higher
rates of M. pneumoniae and C. pneumoniae infection in the asth-
ma group than for the control group. That this difference was
without significance might be resulted from the low number
of enrolled patients and/or geographic factors. 
In connection with the possible relationship between M.
pneumoniae infection and the onset of asthma, several studies
have shown not only a high level of serum total IgE but also
the production of IgE specific to M. pneumoniae or common
allergens during the course of Mycoplasma infection (20, 21).
Koh et al. reported that IL-4 levels and IL-4/IFN-gamma
ratios in bronchoalveolar lavage fluid were significantly higher
in patients with M. pneumoniae than in patients with pneumo-
coccal pneumonia or control participants and the bronchoalve-
olar lavage cytokine data suggested a predominant Th2-like
cytokine response in M. pneumoniae, thus representing a favor-
able condition for IgE production (22). Therefore, further
study and evaluation including measurement of serum total
IgE, specific IgE to M. pneumoniae, and several cytokines are
needed to further understanding of the relationship between
M. pneumoniae or C. pneumoniae infection and asthma.
Our results showed that there was a significantly higher
positive rate for M. pneumoniae in the COPD group than the
control group and although statistical significance was not
noted, higher rates of C. pneumoniae infection in the COPD
group than for the control group. What is the reason for the
high infection rate of C. pneumoniae in patients with bronchial
asthma and COPD? In an animal model, non-cultivable C.
pneumoniae may have been transformed to a cultivable form
after immunosuppression by corticosteroids (23). The addi-
tion of hydrocortisone succinate enhanced the growth of C.
pneumoniae in vitro, and steroid medication has been associated
with significant elevation of C. pneumoniae antibody titers in
bronchial asthma patients and COPD patients (24). Taken
together, the relatively high positive rate of M. pneumoniae and
C. pneumoniae in patients with bronchial asthma and COPD
in our study may be associated with their steroid treatments.
For the clinician, the diagnosis of C. pneumoniae infection
may be difficult because of the lack of availability of diagnostic
facilities for organism identification either serologic testing,
and also because of the controversies surrounding the serodi-
agnostic criteria (12). A serologic method for the diagnosis
of C. pneumoniae infection that is based on MIF has been intro-
duced for both the laboratory and the clinical setting. A four-
fold rise in the IgG titer, an IgM titer higher than 1:16, and
an IgG titer higher than 1:512 have been considered to be con-
sistent with acute infection (25). IgG titers between 1:16 and
1:512 are considered to be evidence of prior infection, but
not recent infection. Although an IgG titer of higher than
1:64 is occasionally suggestive of recent infection (26), our
study defined a serologic positive level for C. pneumoniae as
an IgG titer of higher than 1:512 to have less false positive
results.
In conclusion, M. pneumoniae and C. pneumoniae infection
rates are tended to high in patients with clinically stable bro-
nchial asthma and COPD compared with the control subjects
in our study. The results of this study can present the possi-
bility that M. pneumoniae and C. pneumoniae infections have
close associations with stable bronchial asthma or COPD, but
it is unclear whether infections of M. pneumoniae and C. pneu-
moniae have a direct relation for the pathogenesis of these two
diseases. Therefore, greater evaluation and more study are
needed to further understanding of the pathogenesis and treat-
ment of asthma and COPD.
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